Deviating Products. 4.5.1. NOVARTIS has the right to reject Deviating Products in accordance with the provisions of the Supply Agreement. 4.5.2. NOVARTIS shall be entitled to reject a batch, which does not meet the specifications or is not manufactured according to the agreed procedures, GMP requirements or a valid licence. Any dispute regarding the determination of a deviation or failure’s root-cause or the planned corrective and preventative actions shall be resolved in good faith between both Parties. NOVARTIS shall inform GW in writing of any defects not later than sixty (60) business days after receipt of the products. However, concealed defects, which are typically not discovered by routine quality control measures, may be reported within twenty (20) business days after their discovery (terms may vary, to be aligned with Supply Agreement).
Appears in 3 contracts
Sources: Manufacturing and Supply Agreement, Manufacturing and Supply Agreement (Gw Pharmaceuticals PLC), Manufacturing and Supply Agreement (Gw Pharmaceuticals PLC)